Page 58 - Read Online

Puppala. Hepatoma Res 2019;5:44 I http://dx.doi.org/10.20517/2394-5079.2019.28 Page 9 of 10

Financial support and sponsorship
None.

Conflicts of interest
The author declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Guan YS, He Q, Wang MQ. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol
2012;2012:480650.
2. Friedman MA, Volberding PA, Cassidy MJ. Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil
combined with whole-liver irradiadiation: a Northern California Oncology Group study. Cancer Treat Rep 1979;63:1885-8.
3. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in
the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52.
4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves
survival. Hepatology 2003;37:429-42.
5. Puppala S, Patel R, Yap KS, Patel J, Wah T, et al. Hepatocellular carcinoma: modern image-guided therapies. Postgrad Med J
2016;92:165-71.
6. Raoul JL, Heresbach D, Bretagne JF, Ferrer DB, Duvauferrier R, et al. Chemoembolisation of hepatocellular carcinomas. A study of
the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992;70:585-90.
7. Kang YJ, Lee BC, Kim JK, Yim NY, Kim HO, et al. Conventional versus small doxorubicin-eluting bead transcatheter arterial
chemoembolization for treating barcelona clinic liver cancer stage 0/A hepatocellular carcinoma. Cardiovasc Intervent Radiol 2019;
Epub ahead of print [PMID: 31646378 DOI: 10.1007/s00270-019-02349-9]
8. Puppala S. Management of Post-embolization Syndrome. In: Kessel D, Ray C, editors. Transcatheter Embolization and Therapy.
Techniques in Interventional Radiology. Springer: London; 2010.
9. Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-
analysis. J Dig Dis 2016;17:510-7.
10. Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, et al. Conventional transarterial chemoembolization versus drug-
eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015;15:465.
11. Li H, Wu F, Duan M, Zhang G. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating
hepatocellular carcinoma patients with multiple conventional TACE treatments history: a comparison of efficacy and safety. Medicine
(Baltimore) 2019;98:e15314.
12. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
13. Affonso BB, Galastri FL, da Motta Leal Filho JM, Nasser F, Falsarella PM, et al. Long-term outcomes of hepatocellular carcinoma
that underwent chemoembolization for bridging or downstaging. World J Gastroenterol 2019;25:5687-701.
14. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, et al. Impact of pretransplantation transarterial
chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005;11:767-75.
15. Sun Y, Ji S, Ji H, Liu L, Li C. Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined with
radiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer. J BUON 2019;24:1402-7.
16. Shi F, Wu M, Lian SS, Mo ZQ, Gou Q, et al. Radiofrequency ablation following downstaging of hepatocellular carcinoma by using
transarterial chemoembolization: long-term outcomes. Radiology 2019;293:707-15.
17. Xu Z, Xie H, Zhou L, Chen X, Zheng S. The combination strategy of transarterial chemoembolization and radiofrequency ablation or
microwave ablation against hepatocellular carcinoma. Anal Cell Pathol (Amst) 2019;2019:8619096.
18. Albrecht MH, Vogl TJ, Wichmann JL, Martin SS, Scholtz JE, et al. Dynamic 4D-CT angiography for guiding transarterial
chemoembolization: impact on the reduction of contrast material, operator radiation exposure, catheter consumption, and diagnostic
confidence. Rofo 2018;190:513-20.
19. Hayakawa K, Tanikake M, Kirishima T, Yoshinami N, Shintani H, et al. The incidence of contrast-induced nephropathy (CIN)